carboplatin,etoposide,atezolizumab,tiragolumab
roche
['skyscraper 02']
#asco22 primary endpoint of skyscraper 02 shows no difference in pfs. would not expect these to change with time. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him